michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you, Eric. We actually are not expecting to have much more payment this year. We paid a small amount in July, around $1 million, but this is it. All of the other payments that we have on the balance sheet is -- if everything will going -- goes into plan, we'll pay around Q1 2022.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, until we get our dining rooms full. Once we get those the dining rooms full, and bring back what we would consider our new full menu, that's when you're going to start seeing those percentages going up. And so that's going to be the last -- probably last quarter of this year, going into first quarter of next year.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Demand remains very strong. We don't feel any weakness in demand, 4.7 orders per community per month for the quarter is above the company thought process and where we think a sweet spot for the market is, as I mentioned earlier, and we continue to see that demand. What's causing the order change year-over-year is everybody is comparing the industry to a pandemic, which we've never been through. And frankly, we're all restraining sales releases.
So when you restrain sales releases and rapidly sell homes to the end of 2020 into 2021, and you see all these new community counts coming in 2022, the math is pretty easy. There's not a cyclical downturn here, it's just pure math. And the demand is there, and we continue to see it through the end of the year, as I mentioned earlier, for many of our communities. We'll continue to monitor sales through the rest of this year.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I mean, they're out of service, then we're capitalizing that interest, right? We bring them back service, then we stop that policy. So obviously, PENN 2 is out of service and that we've laid those numbers out in the supplement. PENN 1 today is all in service. So I think that's -- I think it's pretty straightforward, John.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So thank you again for joining us today. So we are -- I hope we convinced you we are poised for significant growth next year, as I just described. That's based on our foundational base business on the VOXZOGO launch in the EMEA region and anticipated in the U.S. next month, also the ROCTAVIAN gene therapy potential -- potentially layered on top of that in mid- to late 2022 as well as deep early stage pipeline that we look forward to sharing with you in -- on November 30 during our virtual R&D Day. So we are focused on continuing this strong momentum as we achieve our next important catalysts, including the potential approval of VOXZOGO in the U.S. by the end of next month. So thank you for your attention today, and we look forward to speaking with you again soon.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Is that you Bonnie, I'll come to you -- yeah, I'll come to you next. We'll do Brett first and then come to you Bonnie. Great. Over to you Brett.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
The primary, as I mentioned earlier, the primary driver is just good, solid demand. The consumption, that is happening in this country, is higher than it's ever been, largely due to COVID. Household savings are the highest they've been. Household debt levels are low. And so you've got all the right fundamentals for people to go out and, of course, try to celebrate life after a year off, but also, they have the capital to do it. So that's what you're seeing. It's flat out strong demand and all of the wrinkles in the supply chain, have a lot to do with that exploding demand, when we aren't fully back to work in a lot of these delivery chains.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I would say that the former William Hill, particularly in the last football season, which is really when the spotlight shown for the first time on this space was fighting with an arm behind their back because of the limbo between signing and closing the transaction. You have enough history with us to know that we are disciplined in our deployment of capital. But we are also sober enough to realize we have to invest considerably more than has been invested historically here.
We think we can do it in an efficient manner because of all of the advantages that we bring to the table. But like I said, we're going to put our heads down and do it. I'm not going to put a stake in the ground and say, we're going to have this much defensible market share by this date. We are very, very early in this process. We've got a great hand to play, and I have tremendous confidence in our ability to operate and be a leader here, and that's what we're setting out to do.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey, this is Ty. I mean, I would say, most of the consolidation that we've seen has been between like legacy Permian operators, most of whom we have existing relationships with. We have gained couple of new additional, strong relationships through some of the consolidations. But I think overall for us, it's been positive across all of our business lines. Just with where our acreage sits, the relationships we have prioritizes some of our acreage that may not have been previous to some of this consolidation. So, I would say, overall, it's been very positive for TPL.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, thanks to all of you for your participation today. We appreciate your questions, and please feel free to call us if you have anything further. Thank you, and have a great day.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Louise. So just commenting on the net price, if you look at our net price over the last many years, you'll see that the net price has been very much stable. And we made sure that over time, we protected that. Today, there is a slightly different dynamic, and you see we're going to be, we said opportunistic because that's not going to be an overarching strategy.
We're only going to do that when we believe it is business meaningful and will drive access to a meaningful business opportunity. I don't believe that that's going to be significant at this stage, simply because we are retaining and even improving our access despite having the two generics available. In fact, many payers recognize the lower net cost benefit of VASCEPA. And for the moment, we have very good coverage at the market level.
We don't see this as a continuing consistent trend. We say we may need to do this from an opportunistic perspective and a number of plans, but that's it, and we'll have to see how things evolve. We're also conscious to ensure that we keep prices similar between different northern parts of the world. As you know, in Europe, we have European reference pricing.
So we will try to maintain our prices level as close as possible to each other and not lose a lot of our value in terms of price.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, I think we described before that we do expect the operational improvements that we're making to materialize in the second half of the year and really, really show up in 2022. Again, with being one of the largest poultry businesses in the world, it takes some time to get those operational improvements back on track. We put Donnie King in place. Have a very strong team there that are really on top of the things that we know that we need to improve to be where we want to be.
The long-term supply/demand dynamics in the classic poultry cycles, I'm not necessarily going to comment on. But I will say that our ability to value up our portfolio into our retail businesses and to add features and attributes that bring new households into our brands and into our poultry business, like you've seen with Air Fried are nothing short of exceptional. I think that gives us a real advantage in the future to expand upon -- to make the business not only competitive, but winning in the space.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. We wouldn't have visibility to that. But what I'll tell you what we do find is that all of our finance -- this is a macro that started before COVID is that all applications, all uses of data, whether it's in banking, credit cards, mortgage, auto, lending, telco, all of our customers want to use more data. And they want to use more differentiated and alternative data, because it enhances the predictability of the decision they're making, and let's use originations. And that's why you're seeing more alternative data being used. We think our cloud transformation is going to differentiate us and the ability to house that data to -- and as well as surface and deliver that data to our customers. And then of course TWN, we talked earlier in this conversation in the call this morning about the power of that dataset in net credit decisioning meaning is someone working, how much are they making, added to the credit file and the other alternative data is very, very powerful.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, I think as we talk about our rollouts, whether it's been in Horizon 1 or 2, I think the product launches are really important. And when we look at what we believe is a strength of ours and industry-leading segmentation, we believe that will continue to be a strength of ours. And so we just -- we're finishing our 8.6 product or are in the midst of that, I should say. We rolled out on the auto side 8.7 in January, and that gives us greater segmentation, which is, again, the right rate for the right risk.
And so I think the product models have always been our strength. We feel the same way on the product side. We're rolling out our next-gen 4.0 product model. And it's always in flux.
So we never say, here's a product model. We'll roll it out and not try to make it better. We try to make it better. So there's a little -- we can have things along the way that will add into the product models once we see -- if it adds value to get more consumers that are profitable consumers.
So that product model period is really important. And it's one of our -- when we think about competitive prices, which, of course, this is such a price-sensitive industry, cost and segmentation are a big advantage for us and very important.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, Erik, this is Gabe. I'll jump in on that. I'm not sure that we're ready to discuss the specific metrics that we'll be talking about on the Analyst Day, but I think you can expect to hear normal types of metrics that are discussed in these types of events. We'll talk about what we believe our long-term leverage profile ought to be.
Of course, that will be influenced by the strategic review that we're undergoing. We'll talk about where we see our development pipeline and potential growth targets over the next several years and our margin targets.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So, we believe that we have with the rare disease franchise, which is Rett syndrome, Fragile X, and others the ability, and it's not the first time that a company has built this into a commercial entity with rare disease -- targeting rare diseases. So, that seems to be very doable. In terms of the indication like Alzheimer's disease and Parkinson's disease, which requires also the involvement of detailing general practitioners, physicians, or general physicians, then it might be more powerful to penetrate the market with the support of a large pharma partner. And at the right time, to make sure that we retain most upsides for Anavex and for our shareholders, this will be done at the right time and not prematurely to give up to much of the upside.
But there's no doubt that these large indications require additional support.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Three percent, Cai.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I mean, across the organization, we did do some headcount reductions. I think we were pretty load though about -- we reinvested some of those savings we took in certain areas back into R&D, so although may be permanent in one sense, we kind of just reallocated back that to the R&D. I was going [Phonetic] to say, if David, you had anything else to add?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I'll just add a very macro level. Polyester grows at the rate of -- polyester production at the rate of 2% to 4% a year depending on GDP and population growth. So that as the virgin -- the recycled materials will grow at a faster rate than that. And it's such a small part of the entire ecosystem right now, there is a huge upside. So it's hard to put a number on it exactly, but it's certainly going to be much higher than the normal virgin growth rates. I think the other thing that I'd like to bring up is that we have REPREVE but we also, as Craig mentioned earlier, we have REPREVE plus and that's the innovation. So we're giving people the sustainability and these performance attributes that I think really resonates with the brands and helps them sell through more products. So we're for selling sustainability. We're also selling sustainability with moisture management terms. So sustainability with antimicrobial, the sustainability with no water being used to make the arm, what we call the water-wine France [Phonetic] or I think there's lots of other opportunities beyond just sustainability.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Todd.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
When you compare year-over-year, you're going to have 1.5 -- in the area of $1 million to $1.5 million in the prior year quarter that's going to be affected by the aviation usage, so the -- it should not be that as much of a decrease in the second quarter as the first because it's kind of apples-to-apples with the aviation impact. And then, as -- sequentially as you go forward, the improvement in air travel should be accretive to the IoT ARPU.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, you can remember our previous guide was four to four one. So the movement of $120 million dropped this down to the three nine to 395. So you can probably like backward engineer and the lower the number was previously.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Tom, one of the things we love about the logistics business is its consistency. That's evident in pricing, and it's evident in the kind of financial results that we're able to generate in a variety of backdrops. So, we're able to manage price movements very well in that business, and you shouldn't expect to see any impact in logistics results based on the movement that you're seeing in transportation markets today. Obviously, to the extent that there are indicators of a strong demand backdrop, that's good for the logistics business as it is for transportation, but generally a constructive backdrop there as well.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I'm sorry, the question is about what? I didn't catch you.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, Scott.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, thanks for the question, Ren. Matt, do you want to take that in terms of data flow coming from the rebastinib program?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
It's a great question. We actually see potential above where we were pre-pandemic, in part because of what we're doing with the portfolio, the better operations, the reinvestment. So we expect to be a few hundred basis points above where we were at the peak prior to the pandemic, high 80% range, maybe 90%. And we'll get there not this year, but we'll get there over the next few years as we deliver these reinvestments and we lease-up around the strength of the new anchors.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
In prostate, I assume? In lung and prostate, or just lung, Jonathan?

    Prediction (one of UP, DOWN, SAME): SAME